REVIEW

713  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence

750  A New Model to Study the Role of Arachidonic Acid in Colon Cancer Pathophysiology
Yang-Yi Fan, Evelyn Callaway, Jennifer M. Monk, Jennifer S. Goldsby, Peiyi Yang, Logan Vincent, and Robert S. Chapkin

758  Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

RESEARCH ARTICLES

721  Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
David C. Montrose, Xi Kathy Zhou, Erin M. McNally, Erika Sue, Rhonda K. Yantiss, Steven S. Gross, Nita D. Leve, Edward D. Karoly, Chen S. Suen, Lilan Ling, Robert Benezza, Eric G. Pamer, and Andrew J. Dannenberg

732  Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses’ Health Studies

739  Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma
Feng Wang, Jian Huang, Zhu Zhu, Xiao Ma, Li Cao, Yongzhi Zhang, Wei Chen, and Yang Dong

766  Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia
Alba Lucía Cómbita, Tariq Gheit, Paula González, Devi Puerto, Raúl Hernando Murillo, Luisa Montoya, Alex Vorsters, Severien Van Keer, Pierre Van Damme, Massimo Tommasino, Gustavo Hernandez-Suarez, Laura Sánchez, Rolando Herrero, and Carolina Wiesner
Celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2), has chemopreventive effects in the gastrointestinal (GI) tract. Although celecoxib is believed to possess anti-tumor activity primarily by suppressing COX-2-derived prostaglandin biosynthesis, it may also act by COX-2-independent mechanisms. The GI tract contains trillions of bacteria which can secrete metabolites known to impact GI tumor development. This study demonstrates that celecoxib treatment shifts the luminal bacterial and metabolite profiles in association with reducing stem cell proliferation and polyp burden in APC<sup>min/+</sup> mice. The cover image shows results of lineage tracing of Lgr5-positive stem cells in the ileal crypt of an Lgr5-EGFP-cre-CreERT2/Rosa26-lacZ mouse given celecoxib. Mice were given either celecoxib-containing diet or control diet for five weeks then tamoxifen was administered and tissues were examined by LacZ staining. The ability of Lgr5-positive cells to give rise to the differentiated cells in the crypt was impaired by celecoxib treatment. Taken together, this study suggests that celecoxib has a previously unrecognized mechanism of action that may contribute to its chemopreventive effects. Namely, altering the microbiota and reducing the growth-promoting metabolites they produce results in decreased stem cell proliferation and reduced polyp burden. See the article by Montrose and colleagues (beginning on page 721) for more information.
Cancer Prevention Research

9 (9)


Updated version
Access the most recent version of this article at:
http://cancerpreventionresearch.aacrjournals.org/content/9/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.